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OBJECTIVES: This study examines the patient level factors that
play role in initiating the process of prior authorization, and
evaluates whether prior authorization (PA) process has an effect
on future gastrointestinal (GI) outcomes (e.g. bleeding, peptic
ulcer disease (PUD)) in managed care population. METHODS:
Patients who encountered a PA system edit for Cox-2 inhibitors
during January 1, 2001 to July 31, 2002 were followed up for
1 year post rejection date. Patients were stratiﬁed to 2 groups;
1) initiated the process of PA, 2) never initiated the process of
PA. Using multivariate logistic regression, signiﬁcant covariates
in predicting future GI bleed or PUD, and applying for PA were
identiﬁed. Charlson Comorbidity Index (CCI) was calculated for
each patient and used in the regression analysis. RESULTS:
Those who initiated the PA process were signiﬁcantly older, had
higher CCI, higher total medical and pharmacy costs, and more
GI events than those who never applied for a PA. Signiﬁcant
covariates in predicting future GI bleed were aged £65, previous
GI bleed or PUD, and higher CCI. In addition to gender similar
covariates also predicted future PUD where females were at
higher risk of having a PUD. Whether prior authorization
process was initiated or not was not a signiﬁcant factor in pre-
dicting future GI event. Patients who are females or age £65,
with osteoarthritis, rheumatoid arthritis, previous ulcer or GI
bleed event, or high CCI score were more likely to apply for PA.
CONCLUSION: PA process appears to select high risk patients
to receive Cox-2 inhibitors. Patients who did not apply for PA
appear to have similar adjusted future GI event rate than those
who applied.
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OBJECTIVES: Assess the construct validity of the GERD-SMQ
in relation to esophagitis grade severity, symptom severity, and
quality of life within a clinical trial. METHODS: The GERD-
SMQ was administered to 1722 subjects participating in a mul-
ticenter, randomized double-blind clinical trial. Subjects had a
history of erosive esophagitis based on an endoscopy (EGD) per-
formed at study entry or a previous EGD within ﬁve years. The
Modiﬁed Hetzel-Dent Grading Scale was used to determine
esophagitis grade scores. A 4-point Likert scale was used to
assess GERD symptoms and the Gastroesophageal Reﬂux
Disease Symptom Assessment Scale (GSAS) distress domain
assessed quality of life (QOL). Logistic regression, using the
GERD-SMQ score (based on previous validation using the heart-
burn + regurgitation + medication subscores) as the independent
variable, was performed to test the GERD-SMQ’s degree of asso-
ciation with esophagitis grade and GERD symptoms. ANOVA
techniques, using QOL as the independent variable, were
employed to test the GERD-SMQ’s degree of association with
QOL scores. RESULTS: Results of ordinal logistic regression
univariate analyses using esophagitis grade score as the depen-
dent variable showed that as GERD-SMQ score increased by one
unit, the odds of having more severe symptoms also increased
signiﬁcantly (OR 1.04, p < 0.05). Using screening symptoms
scores as the dependent variable, the odds of having more severe
symptoms signiﬁcantly increased with observed increases in
GERD-SMQ scores (OR 1.22, p < 0.0001). Analysis of variance
results showed that for every one unit increase in the GSAS 
distress score, the GERD-SMQ score signiﬁcantly increased 
by a factor of 2.39 (p < 0.0001). CONCLUSIONS: Signiﬁcant
relationships exist between the GERD-SMQ score, speciﬁc 
symptoms and clinical severity markers demonstrating that 
the GERD-SMQ is valuable in the clinical trial setting. Further
evaluation of the GERD-SMQ is warranted to determine the 
use of this questionnaire in patients with symptoms of GERD
with or without erosive esophagitis.
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OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR)
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OBJECTIVES: To determine if an IVR intervention was associ-
ated with attainment of the preventive service of inﬂuenza immu-
nization for older adults. METHODS: A MCO in the Eastern
U.S. identiﬁed a cohort of members (n = 22,501) age 65 and over
as of January 1st, 2002 who were eligible for inﬂuenza immu-
nization based on the Health Plan Employer Data and Informa-
tion Set (HEDIS) speciﬁcations. The intervention consisted of
telephone calls with IVR system prompts to remind patients to
get immunized. Rates of adherence were compared based on
whether members received a reminder. Calls were classiﬁed as
reminders if the targeted member was contacted directly, or
called in to the system after having heard the reminder, or if the
reminder was left with another household member or on an
answering machine. Calls were classiﬁed as non-reminders if the
member hung-up, no connection was made, or if the targeted
member or another household member declined the intervention.
The telephone intervention began October 10th, 2002 and ended
January 21st, 2003. Claims data for immunizations were evalu-
ated from October 10th, 2002 to March 31st, 2003. Multivari-
ate logistic regressions evaluated associations between the
intervention and odds of getting the inﬂuenza immunization,
controlling for age group and gender. RESULTS: Of members
receiving the IVR reminder 6.9% got inﬂuenza immunizations,
while 3.2% of members not receiving the reminder got immu-
nizations (p < 0.0001). Logistic regression revealed signiﬁcant
associations between the IVR reminder and the likelihood of
receiving the immunization, controlling for age group and gender
(p < 0.0001). Neither age group nor gender signiﬁcantly affected
the odds of getting an immunization. Members who received a
